Red cell alloimmunization in transfusion-dependent and transfusion-independent beta thalassemia: A review from the Eastern Mediterranean Region (EMRO).


Journal

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 14 06 2019
revised: 25 10 2019
accepted: 28 10 2019
pubmed: 23 11 2019
medline: 1 5 2020
entrez: 23 11 2019
Statut: ppublish

Résumé

β-Thalassemia is considered one of the common hemoglobin disorders in the Arabian Peninsula. Red blood cell (RBC) transfusion is a crucial component of the management of transfusion-dependent β-Thalassemia patients. Patients with Thalassemia Intermedia (TI), also known as non-transfusion dependent β-thalassemia, have a wide clinical presentation and variable transfusion dependence. Rates of RBC alloimmunization and its risk factors in transfusion-dependent β-thalassemia patients varied between different reports. Risk of alloimmunization is higher in TI patients. A literature review on existing reports on alloimmunization rates and risk factors in transfusion dependent and non-transfusion dependent β-thalassemia in the Eastern Mediterranean region was performed. A total of 17 publications were found. Reported rates of alloimmunization among transfusion-dependent β-Thalassemia patients ranged between 2.87 and 30 % and between 6.8 and 19.5 % among TI patients. Most centers utilize ABO and RhD matched RBCs. The most common antibodies described are anti-K and anti-E. The risk factors described included age at onset of transfusion, gender, history of splenectomy, duration of transfusion and number of units transfused. Rate of autoantibody formation ranged between 0.1 and 45 %. Our review showed variable alloimmunization rates and risk factors in thalassemia patients and scant data on TI patients. The commonest antibodies are anti-K and anti-E. Further studies are required in addressing the rate of alloimmunization, cross-match requirements and role of genotyping in this group of patients. Transfusion support of patients with thalassemia necessitates the availability of blood bank facilities and specialized expertise.

Sections du résumé

BACKGROUND BACKGROUND
β-Thalassemia is considered one of the common hemoglobin disorders in the Arabian Peninsula. Red blood cell (RBC) transfusion is a crucial component of the management of transfusion-dependent β-Thalassemia patients. Patients with Thalassemia Intermedia (TI), also known as non-transfusion dependent β-thalassemia, have a wide clinical presentation and variable transfusion dependence. Rates of RBC alloimmunization and its risk factors in transfusion-dependent β-thalassemia patients varied between different reports. Risk of alloimmunization is higher in TI patients.
MATERIAL AND METHODS METHODS
A literature review on existing reports on alloimmunization rates and risk factors in transfusion dependent and non-transfusion dependent β-thalassemia in the Eastern Mediterranean region was performed.
RESULTS RESULTS
A total of 17 publications were found. Reported rates of alloimmunization among transfusion-dependent β-Thalassemia patients ranged between 2.87 and 30 % and between 6.8 and 19.5 % among TI patients. Most centers utilize ABO and RhD matched RBCs. The most common antibodies described are anti-K and anti-E. The risk factors described included age at onset of transfusion, gender, history of splenectomy, duration of transfusion and number of units transfused. Rate of autoantibody formation ranged between 0.1 and 45 %.
CONCLUSION CONCLUSIONS
Our review showed variable alloimmunization rates and risk factors in thalassemia patients and scant data on TI patients. The commonest antibodies are anti-K and anti-E. Further studies are required in addressing the rate of alloimmunization, cross-match requirements and role of genotyping in this group of patients. Transfusion support of patients with thalassemia necessitates the availability of blood bank facilities and specialized expertise.

Identifiants

pubmed: 31753776
pii: S1473-0502(19)30242-3
doi: 10.1016/j.transci.2019.102678
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

102678

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Arwa Z Al-Riyami (AZ)

Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman. Electronic address: arwa.alriyami@gmail.com.

Shahina Daar (S)

Department of Hematology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH